<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04780841</url>
  </required_header>
  <id_info>
    <org_study_id>RDX013-201</org_study_id>
    <nct_id>NCT04780841</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia</brief_title>
  <acronym>Redukx</acronym>
  <official_title>A Two-Part Proof-of-Concept Study: An Open-Label Dose-Ranging Phase (Part A) Followed by a Randomized, Single-Blind, Placebo-Controlled Phase (Part B) Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardelyx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardelyx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the ability of RDX013 to lower serum potassium in&#xD;
      patients with chronic kidney disease with elevated serum potassium levels&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>In Part A, treatment arms will be dosed based on the results from the previous arm. For Part B, one treatment arm from Part A will be selected</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>This is a two part study; Part A is open label and Part B is blinded to study participants (all drug labels for treatment arm and placebo will be identical)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum potassium; Part A</measure>
    <time_frame>1 week</time_frame>
    <description>To evaluate the change of serum potassium from baseline to the end of treatment with different doses of RDX013 to identify the optimal dose for further evaluation in Part B of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum potassium; Part B</measure>
    <time_frame>4 weeks</time_frame>
    <description>To evaluate the difference between RDX013 and placebo in the change of serum potassium from baseline to the end of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exporatory Objective; time to serum potassium normalization</measure>
    <time_frame>4 weeks</time_frame>
    <description>To evaluate the time to initial normalization of serum potassium level (≥3.5 to ≤5.0 mmol/L) during the initial 24 hours of treatment.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hyperkalemia</condition>
  <arm_group>
    <arm_group_label>RDX013 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDX013 low dose oral dosage, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDX013 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDX013 low, mid dose oral dosage, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDX013 Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDX013 high, mid dose oral dosage, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDX013 Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDX013 high dose oral dosage, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDX013 Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDX013 dose from Part A oral dosage, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Part B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral dosage, twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDX013</intervention_name>
    <description>RDX013 is an experimental drug that is a potassium secretagogue</description>
    <arm_group_label>RDX013 Cohort 1</arm_group_label>
    <arm_group_label>RDX013 Cohort 2</arm_group_label>
    <arm_group_label>RDX013 Cohort 3</arm_group_label>
    <arm_group_label>RDX013 Cohort 4</arm_group_label>
    <arm_group_label>RDX013 Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo treatment that looks identical to experimental treatment</description>
    <arm_group_label>Placebo Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females aged 18 to 85 years, inclusive&#xD;
&#xD;
          2. Serum potassium value 5.1 to &lt;6.5 mmol/L&#xD;
&#xD;
          3. Chronic kidney disease with eGFR ≥20 to &lt;60 mL/min/1.73m2&#xD;
&#xD;
          4. Able to understand and comply with the protocol&#xD;
&#xD;
          5. Willing and able to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pseudo-hyperkalemia signs and symptoms&#xD;
&#xD;
          2. Treatment with potassium-lowering drugs within 7 days prior to&#xD;
             enrollment/randomization&#xD;
&#xD;
          3. Treatment with glucocorticoids&#xD;
&#xD;
          4. Uncontrolled Type 2 diabetes, defined as most recent historical HbA1c &gt; 10%, or&#xD;
             hospitalization to treat hyper- or hypo-glycemia in the past 3 months&#xD;
&#xD;
          5. Diabetic ketoacidosis&#xD;
&#xD;
          6. Severe heart failure, defined as NYHA (New York Heart Association) Class IV or&#xD;
             hospitalization to treat heart failure in previous 3 months&#xD;
&#xD;
          7. History of bowel obstruction, severe gastrointestinal disorders, or major&#xD;
             gastrointestinal surgery (e.g., large bowel resection)&#xD;
&#xD;
          8. Females who are pregnant, lactating, or not willing to use appropriate contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jocelyn Tabora</last_name>
    <phone>510-745-1721</phone>
    <email>jtabora@ardelyx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Edelstein, PhD</last_name>
    <email>sedelstein@ardelyx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Horizon Research Group LLC</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Lamas</last_name>
      <phone>305-570-2016</phone>
      <email>llamas@horizonmedresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Panax Clinical Research LLC</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Revoredo</last_name>
      <phone>305-698-4500</phone>
      <email>mrevoredo@panaxcr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Florida Research Phase I-IV; Inc.</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisbelle Revoredo</last_name>
      <phone>305-418-0847</phone>
      <email>lrevoredo@southfloridatrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NW Louisiana Nephrology Assoc</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deanna Mondero</last_name>
      <phone>318-213-2780</phone>
      <email>dmondero@nwln.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consultants</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasmin Hyder</last_name>
      <phone>816-756-1222</phone>
      <email>hyder@crckcmo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mountain Kidney &amp; Hypertension Associates</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Johnson</last_name>
      <phone>828-258-8545</phone>
      <email>tara@mtnkidney.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkalemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

